AstraZeneca’s Imfinzi (durvalumab) plus chemotherapy tripled patient survival at the three-year mark in a phase 3 study for adults suffering from extensive-stage small cell lung cancer.

This is the longest survival follow-up ever reported for an immunotherapy treatment in this setting, the Anglo-Swedish company said.

Imfinzi in combination with different chemotherapies is approved for the first line treatment of extensive-stage small cell lung cancer in over 55 countries, including the U.S., the EU and China. The blockbuster monoclonal antibody earned $2 billion worldwide in 2020.